Viyash Scientific: Animal Health + Life Science, Targeting 1000Cr EBITDA
​Viyash Scientific rebrands, acquires BioForLife Italia, boosts EBITDA margin and expands platform, FY27 to test synergy benefits and CDMO growth.
142 Views
The Beat Ideas: Sequent Scientific Merger - CDMO Optionality with Margin Upside
​NCLT approves Sequent-Viyash merger, creating INR 8,000 Cr+ Life Sciences platform with 56:100 swap ratio and management upgrade.
516 Views
Solara Active Pharma: Carving Out Ibuprofen to Recapture Margin
​Solara's Q1 FY27 net profit up 55% YoY to INR 16.3 crore, debt reduced, considering sale of loss-making Ibuprofen business, potential for margin...
177 Views
Profit from India's Rapidly Growing Biotechnology Industry
Now is a strategic time to focus on the upside potential of biotechnology companies in India, as India’s biotechnology industry is projected to...
5.1k Views
India's Budgets: 2006-2015. Key Charts, and Key questions
In continuation of my work of detailed work on India Budget for last ten years, this piece through simple charts puts in perspective: Â 2014 Actual...
557 Views